Search
Displaying 611–620 of 658 for “retinal diseases”
-
Apellis to Seek FDA Approval of its Dry AMD Drug
Research NewsKnown as APL-2, the drug met its primary endpoint in the OAKS clinical trial but not the DERBY trial
-
Seeing Through Your Disability
Beacon Stories30-year-old Lance Johnson is a video editor and podcaster living in Brooklyn, New York. Despite being diagnosed with retinitis pigmentosa (RP) at a young age, Lance has never let his RP change his drive and passion for creating.
-
Biogen’s Phase 3 Clinical Trial for its Choroideremia Gene Therapy Doesn’t Meet Endpoints
Research NewsAdditional results from the trial will be reported at a future scientific meeting
-
ARVO 2021 Highlight: Update on Clinical Trial of jCyte’s Cellular Therapy for RP
Research NewsCellular treatment provided significant improvements in visual acuity for subpopulation of patients with better vision
-
Beacon Stories
American Banker dubbed her as “the sharpest mind analyzing banking policy today – maybe ever.”
-
Managing Your Mindset, Embracing Your Voice
WellnessCharity’s recent rapid decline in vision due to RP and her daughter’s diagnosis with RP has caused her to open up about her vision loss journey. After getting involved with the Foundation, Charity now feels like she has a voice to help others in the visually impaired community.
-
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Research NewsCompany will seek marketing approval for the emerging therapy
-
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
Research NewsIn a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
-
The Foundation’s best-in-class genetic testing program enables any eye care professional in the US to order no-cost genetic testing through the Foundation’s My Retina Tracker Program and genetic counseling for patients clinically diagnosed with an IRD.
-
AGTC Planning Phase 2/3 Clinical Trial for XLRP Gene Therapy
Research NewsThe company is also expanding its Phase ½ trial for the emerging treatment
